1. Current evidence indicates that roughly this percentage of patients with type 2 diabetes (T2D) are prescribed a glucagon-like peptide 1 receptor agonist (GLP-1 RA).

2. According to current studies, which of the following patient populations is most likely to be prescribed a GLP-1 RA?

3. The GLP-1 RAs exert their physiologic action by all of the following mechanisms EXCEPT:

4. According to the American Diabetes Association (ADA) 2022 Standards of Medical Care in Diabetes, which of the following comorbidities has the strongest evidence to support early use of a GLP-1 RA?

5. According to the ADA 2022 Standards of Medical Care in Diabetes, which of the following medication classes is preferred in patients with T2D and chronic kidney disease (CKD) with albuminuria?

6. When interchanging GLP-1 RA products, which of the following reasons should prompt initiation of the new GLP-1 RA at the lowest dose?

7. Millie uses metformin 500 mg, 2 tablets twice daily; glimepiride 4 mg by mouth once daily; and pioglitazone 30 mg, 1 tablet daily, to manage her blood glucose. Her T2D is not yet at goal, with an A1C of 7.4%. In consultation with her primary care provider, she has agreed to add a GLP-1 RA because she has had a stroke since her last medical visit, which was a year ago. What other considerations should be made at this time as the GLP-1 RA is added to address her glycemic control?

8. Joe desired a more convenient administration and switched from liraglutide to oral semaglutide 8 months ago. Previously he used 1.2-mg liraglutide subcutaneously injected daily. He switched to semaglutide 7 mg daily, which was subsequently titrated to 14 mg daily. Today he presents to your pharmacy to pick up his monthly refill and complains that despite the interchange and dose titration, his A1C and blood glucose readings have remained the same. What counseling points can you provide to help Joe get the best benefit from this therapy?

9. You are a pharmacist member of a multidisciplinary team that manages a population of people with T2D. You are asked to provide follow-up support and education to all patients that receive a new prescription for a GLP-1 RA. Which of the following education points could help mitigate the early side effects associated with GLP-1 RAs?

10. Henry is a 65-year-old man with long-standing, but controlled T2D. He has not been seen by his primary care provider in a few years but has had several changes to his medical history. In the past year, the following has been added to his medical profile: occasional heartburn, insomnia, mild depression, gout, obesity, and ischemic stroke. Today he presents for a review of his medications. What is the primary reason you recommend considering the addition of a long-acting GLP-1 RA for Henry at this time?

« Return to Activity